• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Eligibility for and Preventive Potential of Semaglutide in Overweight and Obese Patients With Myocardial Infarction.

作者信息

Hansen Malene K, Olesen Kevin K W, Gyldenkerne Christine, Thrane Pernille G, Stødkilde-Jørgensen Nina, Mortensen Martin B, Maeng Michael

机构信息

Aarhus University Hospital, Aarhus, Denmark; Aarhus University, Aarhus, Denmark.

Aarhus University Hospital, Aarhus, Denmark.

出版信息

J Am Coll Cardiol. 2024 Mar 5;83(9):956-958. doi: 10.1016/j.jacc.2023.12.029.

DOI:10.1016/j.jacc.2023.12.029
PMID:38418010
Abstract
摘要

相似文献

1
Eligibility for and Preventive Potential of Semaglutide in Overweight and Obese Patients With Myocardial Infarction.司美格鲁肽在超重和肥胖心肌梗死患者中的适用性及预防潜力
J Am Coll Cardiol. 2024 Mar 5;83(9):956-958. doi: 10.1016/j.jacc.2023.12.029.
2
Once-Weekly Semaglutide Is an Effective Adjunct for Weight Loss in Adults without Diabetes Who Are Overweight or Obese.司美格鲁肽每周一次给药，对超重或肥胖的非糖尿病成人患者减肥有效。
Am Fam Physician. 2021 Jul 1;104(1):96-97.
3
Population-level impact of semaglutide 2.4 mg in patients with obesity or overweight and cardiovascular disease: A modelling study based on the SELECT trial.司美格鲁肽2.4毫克对肥胖或超重且患有心血管疾病患者的人群水平影响：一项基于SELECT试验的建模研究
Diabetes Obes Metab. 2025 Jun;27(6):3442-3452. doi: 10.1111/dom.16370. Epub 2025 Apr 4.
4
In adults with overweight or obesity and CVD, but without diabetes, semaglutide reduced MACE at a mean 40 mo.在超重或肥胖且患有 CVD 但无糖尿病的成年人中，司美格鲁肽可使 MACE 平均降低 40 个月。
Ann Intern Med. 2024 Mar;177(3):JC31. doi: 10.7326/J24-0008. Epub 2024 Mar 5.
5
Comment on: Semaglutide and cardiovascular outcomes in obesity without diabetes.关于《司美格鲁肽与无糖尿病肥胖患者的心血管结局》的评论
J Endocrinol Invest. 2024 May;47(5):1047-1049. doi: 10.1007/s40618-023-02290-2. Epub 2023 Dec 29.
6
Semaglutide effects on safety and cardiovascular outcomes in patients with overweight or obesity: a systematic review and meta-analysis.司美格鲁肽对超重或肥胖患者安全性及心血管结局的影响：一项系统评价与荟萃分析
Int J Obes (Lond). 2025 Jan;49(1):21-30. doi: 10.1038/s41366-024-01646-9. Epub 2024 Oct 12.
7
Ease-of-use and acceptability of the novel semaglutide 2.4 mg single-dose pen-injector in people with overweight or obesity in the STEP 8 phase III trial.司美格鲁肽2.4毫克单剂量笔式注射器在STEP 8三期试验中对超重或肥胖人群的易用性和可接受性。
Diabetes Obes Metab. 2022 Nov;24(11):2273-2276. doi: 10.1111/dom.14809. Epub 2022 Aug 7.
8
Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes.司美格鲁肽、肥胖相关心力衰竭与2型糖尿病
N Engl J Med. 2024 Jul 25;391(4):381. doi: 10.1056/NEJMc2406233.
9
Real-world effectiveness of Semaglutide treatment on weight loss maintenance after weight loss in patients with obesity or overweight and diabetes.司美格鲁肽治疗对肥胖或超重合并糖尿病患者减重后体重维持的真实世界有效性。
Eat Weight Disord. 2025 Jan 9;30(1):2. doi: 10.1007/s40519-024-01711-2.
10
[For obese patients or for patients who are overweight and have an associated comorbidity, how safe and effective is semaglutide as compared with placebo as an adjunct to lifestyle intervention for reducing body weight and other related end points?].对于肥胖患者或超重且伴有合并症的患者，与安慰剂相比，司美格鲁肽作为生活方式干预的辅助手段用于减轻体重及其他相关终点时，其安全性和有效性如何？
Rev Med Interne. 2021 May;42(5):369-370. doi: 10.1016/j.revmed.2021.03.334. Epub 2021 Apr 8.

引用本文的文献

1
Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies.关于新型基于胰高血糖素样肽-1受体激动剂（GLP-1RA）的减肥疗法的使用、临床及对比疗效和不良反应的真实世界证据。
Diabetes Obes Metab. 2025 Apr;27 Suppl 2(Suppl 2):66-88. doi: 10.1111/dom.16364. Epub 2025 Apr 8.
2
Opportunities for General Internal Medicine to Promote Equity in Obesity Care.普通内科促进肥胖症护理公平性的机遇。
J Gen Intern Med. 2024 Oct 16. doi: 10.1007/s11606-024-09084-z.